Dose-dependent alterations in the metabolome during radiation nephropathy: current insights and biomarker discovery prospects
https://doi.org/10.18705/2311-4495-2026-13-4-371-387
Abstract
Ionizing radiation has a pronounced nephrotoxic effect, initiating a cascade of pathophysiological processes leading to the development of radiation nephropathy (RN) and renal failure. This review is devoted to an analysis of the current state of research in the field of identifying metabolomic biomarkers that allow for early diagnosis and prediction of radiationinduced kidney damage under external irradiation. The paper systematizes literature data obtained using mass spectrometry (MS) and nuclear magnetic resonance (NMR) regarding changes in the profiles of lowmolecularweight metabolites in urine. The main focus is on profound disturbances in purine metabolism (primarily due to the accumulation of xanthine and hypoxanthine), critical shifts in the tricarboxylic acid cycle (TCA), reflecting mitochondrial dysfunction, as well as an imbalance in the lipid profile, including the accumulation of acylcarnitines. These metabolic alterations are key indicators of oxidative stress and proximal tubule dysfunction, and the degree of their severity directly correlates with clinical and dosimetric parameters. The review provides a detailed examination of critical dose thresholds: moderate functional changes manifest when the absorbed dose to the kidneys exceeds 4 Gy, while irreversible structural degradation and manifest RN develop when the threshold of 10 Gy is exceeded. The authors emphasize that the introduction of metabolomic profiling into clinical practice can radically improve the effectiveness of monitoring the condition of patients who have undergone radiation exposure. Unlike classical protein damage markers (NGAL, KIM1), which are sensitive only at late stages, dynamic patterns of acylcarnitines, TCA cycle intermediates, and purine metabolites make it possible to carry out early biodosimetry. This makes it possible not only to detect the fact of radiation damage but also to assess the received radiation dose in the very first hours after exposure, enabling timely nephroprotective therapy.
About the Authors
Yu. V. ShiryaevaRussian Federation
Yulia V. Shiryaeva, Assistant, Department of Nuclear Medicine and Radiation Technologies with Clinic
St. Petersburg
Competing Interests:
The authors declare no conflict of interest
N. V. Mikhailova
Russian Federation
Ninel V. Mikhailova, PhD in Chemical Sciences, Associate Professor, Head of the Department of Chemistry and Biochemistry
St. Petersburg
Competing Interests:
The authors declare no conflict of interest
D. V. Ryzhkova
Russian Federation
Darya V. Ryzhkova, MD, DSc, Professor of the Russian Academy of Sciences, Head of the Department of Nuclear Medicine and Radiation Technologies with the Clinic
St. Petersburg
Competing Interests:
The authors declare no conflict of interest
References
1. Chhabra A, Stabinska J, Piccolo J et al. Early detection of radiation induced nephropathy: external beam vs Ac-225 response. Journal of Nuclear Medicine. 2024; 65: 242258;
2. Li M, Planells CR, Liu D et al. Preclinical evaluation of biomarkers for the early detection of nephrotoxicity following alphaparticle radioligand therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2024; 51:1395–1408.
3. Pannkuka EL, Laiakisa EC, Authierb S et al. Global Metabolomic Identification of Long-Term Dose-Dependent Urinary Biomarkers in Nonhuman Primates Exposed to Ionizing Radiation. Radiation Research. 2015, 184 (2): 121–133.
4. Klaus R, Niyazi M and Sperandio BL et al. Radiation-induced kidney toxicity: molecular and cellular pathogenesis. Radiation Oncology, 2021; 16:43.
5. Vesnina JV. New and potential biomarkers of acute kidney injury. Clinical laboratory diagnostics. 2018; 63:7. In Russian [Веснина Ж.В., Новые и потенциальные биомаркеры острого повреждения почек. Клиническая лабораторная диагностика. 2018; 63:7].
6. Niemann CU, Serkova NJ. Biochemical mechanisms of nephrotoxicity: application for metabolomics. Informa Healhcare, Expert Opinion on Drug Metabolism & Toxicology. 2007, 3:4.
7. Cheshik, A. A. Long-term effects of low-dose radiation exposure. Journal of the Grodno State Medical University. 2026, 24 (1): 13-23. In Russian [Чешик, А. А. Отдаленные последствия низкодозовых радиационных воздействий . Журнал Гродненского государственного медицинского университета. 2026, 24 (1): 13-23].
8. Qiu S, Cai Y, Yao H, et al. Small molecule metabolites: discovery of biomarkers and therapeutic targets. Signal Transduction and Targeted Therapy. 2023, 8:132.
9. Roh C. Metabolomics in Radiation-Induced Biological Dosimetry: A Mini-Review and a Polyamine Study. Biomolecules. 2018, 8: 34.
10. Kalantari S, Nafar M. An update of urine and blood metabolomics in chronic kidney disease. Biomarkers in Medicine. 2019, 13 (7): 577–596.
11. Zhao M, Lau KKT, Zhou X et al. Urinary metabolic signatures and early triage of acute radiation exposure in rat model. Molecular BioSystems. 2017, 13 (4): 756-766.
12. Emwas AH, Roy R, McKay RT et al. NMR Spectroscopy for Metabolomics Research. Metabolites. 2019, 9: 123.
13. Jouret F, Leenders J, Poma L et al. Nuclear Magnetic Resonance Metabolomic Profiling of Mouse Kidney, Urine and Serum Following Renal Ischemia/Reperfusion Injury. PLoS ONE. 2016, 11(9): e0163021.
14. Hajnajafi K, Iqbal MA. Mass‑spectrometry based metabolomics: an overview of workflows, strategies, data analysis and applications. Proteome Science. 2025, 23:5.
15. Abbiss H, Maker GL, Trengove RD. Metabolomics Approaches for the Diagnosis and Understanding of Kidney Diseases. Metabolites. 2019, 9: 34.
16. Menon SS, Uppal M, Randhawa S et al. Cheema and Anatoly Dritschilo. Radiation Metabolomics: Current Status and Future Directions. Frontiers in Oncology, 2016, 6: 20.
17. Tyburski JB, Patterson AD, Krausz KW et al. Radiation Metabolomics. Dose- and Time-Dependent Urinary Excretion of Deaminated Purines and Pyrimidines after Sublethal Gamma-Radiation Exposure in Mice. Radiation Research, 2009, 172: 42–57.
18. Laiakis EC, Mak TD, Strawn SJ et al. Global Metabolomic Responses in Urine from Atm Deficient Mice in Response to LD50/30 Gamma Irradiation Doses. Environmental and Molecular Mutagenesis. 2018, 59(7):576-585.
19. Kartsova L.A., Makeeva D.V. Capillary electrophoresis method: biomedical applications. Laboratory and production. 2023, 2:24. In Russian: [Карцова Л.А., Макеева Д.В., Метод капиллярного электрофореза: биомедицинские приложения. Лаборатория и производство. 2023, 2:24].
20. Yezerskaya A. A., Pivovar M. L. Capillary electrophoresis: basic principles, application in pharmaceutical analysis. Bulletin of Pharmacy. 2019, 1: 83. In Russian [Езерская А. А., Пивовар М. Л. Капиллярный электрофорез: основные принципы, применение в фармацевтическом анализе. Вестник фармации. 2019, 1: 83].
21. Kazachenko A.V., Voitko D.A., Prosyannikov M.Yu. et al. Modern markers for determining the functional ability of the kidneys in urological practice. Experimental and Clinical Urology. 2023, 1:174-187. In Russian: [Казаченко А.В., Войтко Д.А., Просянников М.Ю. и др. Современные маркеры определения функциональной способности почек в урологической практике. Экспериментальная и клиническая урология, 2023. 1: 174-187].
22. Shakyawar SK, Mishra NK, Vellichirammal NN et al. A review of radiation-induced alterations of multi-omic profiles, radiation injury biomarkers, and countermeasures. Radiation Research, 2023. 199(1): 89–111.
23. Vicente E, Vujaskovic Zeljko, Jackson IL. A Systematic Review of Metabolomic and Lipidomic Candidates for Biomarkers in Radiation Injury. Metabolites, 2020. 10: 259.
24. Laiakis EC, Mak TD, Anizan S et al. Development of a metabolomic radiation signature in urine from patients undergoing total body irradiation. Radiation Research. 2014, 181(4): 350-361.
25. Sharma M, Halligan BD, Wakim BT et al. The urine proteome as a biomarker of radiation injury. Proteomics Clin. Appl. 2008, 2: 1065–1086.
26. Pellegrini G, Siwowska K, Haller S. A short-term biological indicator for long-term kidney damage after radionuclide therapy in mice. Pharmaceuticals. 2017, 10(2): 57.
27. Erbas B, Tuncel M. Renal Function Assessment During Peptide Receptor Radionuclide Therapy. Seminars of Nuclear Medicine. 2016, 46(5): 462-78.
28. Zhang Y, Zhou X, Li C et al. Assessment of early triage for acute radiation injury in rat model based on urinary amino acid target analysis. Molecular BioSystems. 2014, 10: 1441-1449.
29. Tyagi R, Maan K, Khushu S et al. Urine metabolomics based prediction model approach for radiation exposure. Scientific Reports. 2020, 10(1): 16063.
30. Kaladi MR, Poldy A, Mukherjee S et al. Multi-faceted approach for identifying biomarkers for radiation injury and regulatory approval of radiation medical countermeasures. The European Physical Journal Special Topics. https://doi.org/10.1140/epjs/s11734-025-01475-5 (03 February 2025).
31. Wei J, Wang B, Wang H et al. Radiation-Induced Normal Tissue Damage: Oxidative Stress and Epigenetic Mechanisms. Oxidative Medicine and Cellular Longevity. 2019, 4:1-11.
32. Ruysscher DD, Niedermann G, Burnet NG et al. Radiotherapy toxicity. Nature reviews| Disease primes, 2019, 5:13.
33. Singh VK, Seed TM, Cheema AK. Metabolomics-based predictive biomarkers of radiation injury and countermeasure efficacy: current status and future perspectives. Expert Review of Molecular Diagnostics. 2021, 21(7): 641-654.
34. Pepanyan A.A., Ghazaryan P.A., Asoyan A.U. et al. Membrane aspects of the pathogenesis of renal complications in radiation damage. Nephrology. 2006, 10 (4): 77-81. In Russian: [Пепанян А.А., Казарян П.А., Асоян А.У. и др. Мембранные аспекты патогенеза почечных осложнений при радиационном поражении. Нефрология. 2006, 10 (4): 77-81].
35. Gramatyka M, Sokół M. Radiation metabolomics in the quest of cardiotoxicity biomarkers: the review. International Journal of Radiation Biology. 2020, 96(3): 349-359.
36. Khan AR, Rana P, Tyagi R et al. NMR spectroscopy based metabolic profiling of urine and serum for investigation of physiological perturbations during radiation sickness. Metabolomics. 2011, 7:583–592.
37. Satyamitra MM, Cassatt DR, Hollingsworth BA et al. Metabolomics in Radiation Biodosimetry: Current Approaches and Advances. Metabolites, 2020, 10: 328.
38. Lanz C, Patterson AD, Slavík J et al.Radiation Metabolomics. 3. Biomarker Discovery in the Urine of GammaIrradiated Rats Using a Simplified Metabolomics Protocol of Gas Chromatography-Mass Spectrometry Combined with Random Forests Machine Learning Algorithm. Radiation Research. 2009, 172(2): 198-212.
39. Johnson CH, Patterson AD, Krausz KW et al. Radiation Metabolomics. 4. UPLC-ESI-QTOFMS-Based Metabolomics for Urinary Biomarker Discovery in Gamma-Irradiated Rats. Radiation Research. 2011, 175: 473–484.
40. Mak TD, Tyburski JB, Krausz KW et al. Exposure to ionizing radiation reveals global doseand time-dependent changes in the urinary metabolome of rat. Metabolomics. 2014, 11(5): 1082–1094.
41. Unthank JL, Ortiz M, Trivedi H et al. Cardiac and Renal Delayed Effects of Acute Radiation Exposure: Organ Differences in Vasculopathy, Inflammation, Senescence and Oxidative Balance. Radiation Research. 2019, 191: 383–397.
42. Abecassis A, Hermano E, Sheva K et al. Radiation-Induced Nephropathy in the Murine Model Is Ameliorated by Targeting Heparanase. Biomedicines. 2023, 11: 710.
43. Бала А .Ю., Черных Т. М. Микроальбуминурия у пациентов, имеющих риск развития хронической болезни почек. Прикладные информационные аспекты медицины. Научно-практический журнал. 2019, 22:2.
44. Ahmad A, Shi J, Ansari S et al. Noninvasive assessment of radiation-induced renal injury in mice. International Journal of Radiation Biology. 2021, 97: 5, 664–674.
45. Ahmada A, Shia J, Ansaria S et al. Radiation nephropathy: Mechanisms of injury and recovery in a murine model. Radiotherapy and oncology. 2023, 187: 109813.
46. Wu X, Zhu T, Li H et al. Study on urine biomarkers of radiation-induced injury guided by Caenorhabditis elegans as a model organism. Radiation Medicine and Protection. 2021, 2: 89–94.
47. Maan K, Tyagi R, Dutta A et al. Comparative metabolic profiles of total and partial body radiation exposure in mice using an untargeted metabolomics approach. Metabolomics, 2020, 16:124.
48. Li Y, Bansal S, Singh B et al. Distinct Urinary Metabolite Signatures Mirror In Vivo Oxidative Stress-Related Radiation Responses in Mice. Antioxidants. 2025, 14: 24.
49. Fish BL, MacVittie TJ, Gao F et al. Rat Models of Partial-body Irradiation with Bone Marrow-sparing (Leg-out PBI) Designed for FDA Approval of Countermeasures for Mitigation of Acute and Delayed Injuries by Radiation. Health Phys. 2021, 121(4): 419–433.
50. Johnson CH, Patterson AD, Krausz KW et al. Radiation Metabolomics. 5. Identification of Urinary Biomarkers of Ionizing Radiation Exposure in Nonhuman Primates by Mass Spectrometry-Based Metabolomics. Radiation Research, 2012, 178(4): 328-340.
51. Cohen EP, Hankey KG, Bennett AW, et al. Acute and Chronic Kidney Injury in a Non-Human Primate Model of Partial-Body Irradiation with Bone Marrow Sparing. Radiation Research. 2017, 188(6):661-671.
52. Moulder JE, Cohen EP. Radiation-induced multi-organ involvement and failure: the contribution of radiation effects on the renal system. The British journal of Radiology. 2005, 27(1):82-8.
53. Pannkuk EL, Laiakis EC, Gill K, et al. Liquid Chromatography−Mass Spectrometry-Based Metabolomics of Nonhuman Primates after 4 Gy Total Body Radiation Exposure: Global Effects and Targeted Panels. J. Proteome Res. 2019, 18: 2260−2269.
54. Carpenter AD, Li Y, Fatanmi OO, et al. Metabolomic Profiles in Tissues of Nonhuman Primates Exposed to Either Total- or Partial-Body Radiation. Radiation Research. 2026, 201(5) : 371-383.
55. Cheema AK, Mehta KY, Rajagopal MU, et al. Metabolomic Studies of Tissue Injury in Nonhuman Primates Exposed to Gamma-Radiation. International Journal of Molecular Sciences, 2019, 20: 3360.
56. Siew K, Nestler KA, Nelson C, et al. Cosmic kidney disease: an integrated panomic, physiological andmorphological study into spaceflight-induced renal dysfunction. Nature Communications, 2024, 15:4923.
57. Hladik D, Bucher M, Endesfelder D, et al. The Potential of Omics in Biological Dosimetry. Radiation. 2022, 2: 78–90.
58. Kosowski E, Olson JD, Gardin J, et al. Long-term Radiation Signal Persistence in Urine and Blood: A Two-year Analysis in Non-human Primates Exposed to a 4 Gy Total-Body Gamma-Radiation Dose. Radiation Research. 2024, 204(4): 343-353.
59. Grant EJ, Yamamura Mariko, Brenner Alina V et al. Radiation Risks for the Incidence of Kidney, Bladder and Other Urinary Tract Cancers: 1958–2009. Radiation Research. 2020, 195(2):140-148.
60. Goudarzi M, Weber W, Mak TD et al. Development of Urinary Biomarkers for Internal Exposure by Cesium-137 Using a Metabolomics Approach in Mice. Radiation Research. 2013, 181(1):54-64.
61. Yang P, Bai H, Yan T et al. Integrative multi-omics analysis of radionuclide-induced intestinal injury reveals the radioprotective role of L-citrulline through histone H3-mediated Cxcl3. Yang et al. Journal of Translational Medicine. 2025, 23:180.
62. Bragina O.D., Vorobyeva A.G., Tolmachev V.M. et al. In vitro and in vivo evaluation of a radiochemical compound based on the 99mTc-labeled DARPin9_29 scaffold protein for molecular imaging of malignancies with Her2/neu overexpression. Medical radiology and radiation safety. 2020; 65(1):37-41. In Russian: [Брагина О.Д., Воробьева А.Г., Толмачев В.М. и др. In vitro и in vivo оценка радиохимического соединения на основе меченного 99mTс каркасного белка DARPin9_29 для молекулярной визуализации злокачественных образований с гиперэкспрессией Her2/neu. Медицинская радиология и радиационная безопасность. 2020; 65(1): 37-41].
63. Widjaja L, Siegmund SC, Gildehaus J, et al. PET-based risk stratification for adverse events under [225Ac]Ac-PSMA radioligand therapy. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-07788-4 (09 February 2026).
64. Li M, Robles‑Planells C, Liu D, et al. Pre‑clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha‑particle radioligand therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2024, 51: 1395–1408.
65. Schüler E, Larsson M, Parris TZ, et al. Potential Biomarkers for Radiation-Induced Renal Toxicity following 177Lu-Octreotate Administration in Mice. PLoS ONE, 2015, 10(8): e0136204.
66. Erbas B, Tuncel M. Renal Function Assessment During Peptide Receptor Radionuclide Therapy. Seminars in Nuclear Medicine. 2016, 46(5): 462-78.
67. Bodei L, Cremonesi M, Ferrari M et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. European Journal of Nuclear Medicine and Molecular Imaging. 2008, 35:1847–1856
68. Tian YG, Yue M, Nashun B, et al. The diagnostic value of [18F]‑FDG‑PET/CT in assessment of radiation renal injury in Tibet minipigs model. Journal of Translational Medicine. 2018, 16: 257.
69. Goudarzi M, Weber WM, Mak TD, et al. A Comprehensive Metabolomic Investigation in Urine of Mice Exposed to Strontium-90. Radiation Research. 2015, 183: 665–674.
70. Grison S, Fave G, Maillot M, et al. Metabolomics reveals dose effects of low-dose chronic exposure to uranium in rats: identification of candidate biomarkers in urine samples. Metabolomics. 2016, 12:154.
71. Okaneku J, Vearrier D, Mckeever R, et al. Urine uranium concentrations and renal function in residents of the United States—2001 to 2010. Clinical Toxicology. 2015, 53:10, 931-934.
Review
For citations:
Shiryaeva Yu.V., Mikhailova N.V., Ryzhkova D.V. Dose-dependent alterations in the metabolome during radiation nephropathy: current insights and biomarker discovery prospects. Translational Medicine. 2026;13(4):371-387. (In Russ.) https://doi.org/10.18705/2311-4495-2026-13-4-371-387
JATS XML





















